BioSpace News Archive

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced their participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021.

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced financial results for the quarter ending March 31, 2021 and provided a corporate update.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma cohort in its registration-enabling clinical trial of anti-PD-L1 antibody, cosibelimab.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2

Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488.

- First and only FDA-approved orthokeratology contact lens for myopia management. - Available in sphere and toric designs to correct various combinations of corneal shapes and refractive errors.

INOVIO’s Pan-SARS-CoV-2 vaccine candidate INO-4802 is not matched to a single variant, unlike other variant vaccines in development; INO-4802 could potentially offer broader immune responses [12-May-2021] PLYMOUTH MEETING, Pa. , May 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology com

Inscopix Inc. a leading neurotechnology company in California that empowers breakthroughs in brain science announced the signing of a distribution agreement with Animalab, a prominent neuroscience distributor in Poland, Czech Republic, Hungary, Slovakia, Latvia, Lithuania, Estonia, Croatia and Slovenia.